bm ascs Search Results


bm ascs  (InvivoGen)
96
InvivoGen bm ascs
A) Experimental diagram. B) wnnUMAPs of <t>ASCs</t> colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) <t>Percent</t> <t>ASC</t> subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.
Bm Ascs, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bm ascs/product/InvivoGen
Average 96 stars, based on 1 article reviews
bm ascs - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
asc basal medium asc-bm  (Lonza)
90
Lonza asc basal medium asc-bm
A) Experimental diagram. B) wnnUMAPs of <t>ASCs</t> colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) <t>Percent</t> <t>ASC</t> subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.
Asc Basal Medium Asc Bm, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/asc basal medium asc-bm/product/Lonza
Average 90 stars, based on 1 article reviews
asc basal medium asc-bm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
immunological platform  (Inserm Transfert)
90
Inserm Transfert immunological platform
A) Experimental diagram. B) wnnUMAPs of <t>ASCs</t> colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) <t>Percent</t> <t>ASC</t> subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.
Immunological Platform, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunological platform/product/Inserm Transfert
Average 90 stars, based on 1 article reviews
immunological platform - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
rbm35b antibody  (Abcepta)
N/A
   Buy from Supplier
bms-8  (Biosynth Carbosynth)
N/A
   Buy from Supplier
rat brain microvascular endothelial cells: rbmvec  (Cell Applications Inc)
N/A
Rat Brain Microvascular Endothelial Cells (RBMVEC) from Cell Applications, Inc. provide an excellent model system to study many aspects of endothelial function and disease, especially those related to the blood-brain barrier (BBB), including interactions between
   Buy from Supplier
bmi 1 antibody  (Abcepta)
N/A
   Buy from Supplier
vasculits and anti gbm associated diseases gbm antibody assays  (Thermo Fisher)
N/A
   Buy from Supplier
rbm35a antibody  (Abcepta)
N/A
   Buy from Supplier
mouse anti-human bmi1 (ascites)  (RayBiotech)
N/A
Mouse Anti-Human BMI1 (ascites) Antibody, 0.1 ml
   Buy from Supplier
rbm23 antibody  (Abcepta)
N/A
   Buy from Supplier
bmf antibody  (Abcepta)
N/A
   Buy from Supplier

Image Search Results


A) Experimental diagram. B) wnnUMAPs of ASCs colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) Percent ASC subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.

Journal: bioRxiv

Article Title: Multi-omic profiling of human antibody-secreting cells reveals diverse subsets sustain durable humoral immunity

doi: 10.64898/2026.04.13.717827

Figure Lengend Snippet: A) Experimental diagram. B) wnnUMAPs of ASCs colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) Percent ASC subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.

Article Snippet: For the ASC culture condition screen, total BM ASCs were stimulated for 72 hours with CpG ODN 2006 (10μg/mL, Invivogen) or BCR crosslinker (anti-kappa light chain; 1μg/mL, Southern Biotech) with various combinations of stimulatory reagents, including MEGACD40L (0.1μg/ml, Enzo Life Sciences), BAFF (1μg/mL, PeproTech), CXCL12 (0.1μg/ml, R&D Systems), IL-2 (0.1μg/mL, Biolegend), and IL-21 (0.1μg/mL, PeproTech).

Techniques: Fluorescence, Spatial Proteomics

A) Experimental diagram. B) Serum Ig concentrations of patients with NDMM by timepoint (x-axis), isotype (y-axis), and the isotype of each patient’s malignant cell (shapes). Transparency indicates values outside the healthy reference ranges specified in the clinical reports. Data from clinical quantitative Ig assay. C) Percent ASCs of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001 D) Percent non-malignant ASCs of total ASCs for patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to PRETX. Data from MM longitudinal BM CITEseq. ***Q<0.001 E) Percent non-malignant ASC subset of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis) and subset (panels). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001

Journal: bioRxiv

Article Title: Multi-omic profiling of human antibody-secreting cells reveals diverse subsets sustain durable humoral immunity

doi: 10.64898/2026.04.13.717827

Figure Lengend Snippet: A) Experimental diagram. B) Serum Ig concentrations of patients with NDMM by timepoint (x-axis), isotype (y-axis), and the isotype of each patient’s malignant cell (shapes). Transparency indicates values outside the healthy reference ranges specified in the clinical reports. Data from clinical quantitative Ig assay. C) Percent ASCs of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001 D) Percent non-malignant ASCs of total ASCs for patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to PRETX. Data from MM longitudinal BM CITEseq. ***Q<0.001 E) Percent non-malignant ASC subset of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis) and subset (panels). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001

Article Snippet: For the ASC culture condition screen, total BM ASCs were stimulated for 72 hours with CpG ODN 2006 (10μg/mL, Invivogen) or BCR crosslinker (anti-kappa light chain; 1μg/mL, Southern Biotech) with various combinations of stimulatory reagents, including MEGACD40L (0.1μg/ml, Enzo Life Sciences), BAFF (1μg/mL, PeproTech), CXCL12 (0.1μg/ml, R&D Systems), IL-2 (0.1μg/mL, Biolegend), and IL-21 (0.1μg/mL, PeproTech).

Techniques: